[{"question_number":"2","question":"What is the pathology of Ependymoma?","options":["Roussate","Pseudorossate"],"correct_answer":"B","correct_answer_text":"Pseudorossate","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is B. Ependymomas classically demonstrate perivascular pseudorosettes\u2014tumor cells radially arranged around blood vessels with an intervening zone of fine fibrillary processes. Option A (\u201cRoussate\u201d) is not a recognized histopathologic pattern in CNS tumor classification and likely reflects a spelling error or misnomer. Extensive neuropathology literature, including the WHO Classification of Tumours of the Central Nervous System (2021), confirms that perivascular pseudorosettes are a defining microscopic feature of ependymoma.","conceptual_foundation":"Ependymomas arise from radial glial\u2013derived ependymal cells lining the ventricular system and central canal of the spinal cord. According to ICD-11 codes 2B11.0\u20132B11.4, they are subdivided by location and molecular profile (e.g., RELA fusion\u2013positive in supratentorial tumors). Historically described by Bailey and Cushing in the 1920s, modern taxonomy incorporates histologic grade (WHO I\u2013III) and genetically defined subtypes. Embryologically, ependymal cells derive from neuroectoderm, with lineage markers such as GFAP and vimentin expressed in neoplastic cells.","pathophysiology":"Normal ependymal cells facilitate CSF movement and form part of the blood\u2013CSF barrier. Neoplastic transformation involves dysregulation of cell cycle pathways (e.g., cyclin D1 overexpression) and activation of oncogenic fusions (e.g., C11orf95\u2013RELA) that drive proliferation. At the microscopic level, formation of pseudorosettes reflects preserved ependymal polarity and cytoplasmic processes oriented toward vessels. Molecular studies reveal aberrant NF-\u03baB signaling in RELA-positive tumors, promoting survival and angiogenesis.","clinical_manifestation":"Intracranial ependymomas present with headache, nausea, vomiting, and papilledema due to obstructive hydrocephalus; posterior fossa tumors cause cerebellar signs and cranial nerve deficits; spinal ependymomas present with pain, motor weakness, and sensory changes. Supratentorial lesions may present with seizures. Natural history varies by grade: WHO I (myxopapillary) are indolent, whereas WHO III (anaplastic) have aggressive behavior with median survival <5 years without adjuvant therapy.","diagnostic_approach":"First-line imaging is MRI with and without contrast: ependymomas appear as iso- to hypointense on T1, hyperintense on T2, with heterogeneous enhancement and possible calcifications. CSF cytology may detect tumor cells in high-grade cases. Definitive diagnosis requires surgical biopsy with histology demonstrating perivascular pseudorosettes and immunohistochemistry positive for GFAP and EMA (dot-like staining). Molecular testing for RELA fusions is recommended by WHO guidelines (Level A evidence).","management_principles":"Gross total resection is the goal; extent of resection is the strongest prognostic factor (5-year PFS ~80% with GTR vs. ~50% with STR). Adjuvant focal radiotherapy is recommended for WHO II\u2013III ependymomas at 59.4 Gy in 33 fractions (Class I, Level A recommendation). Chemotherapy (e.g., vincristine, etoposide) may be considered in recurrent or metastatic disease, though benefit is modest.","follow_up_guidelines":"Postoperative MRI at 3 months to establish baseline, then every 6 months for 2 years, annually up to year 5, and biannually thereafter (AANS/CNS practice parameter). Clinical follow-up includes neurologic exam and assessment for hydrocephalus or cranial neuropathies. Late complications such as secondary neoplasms or neurocognitive deficits warrant lifelong surveillance.","clinical_pearls":"1. Ependymomas show perivascular pseudorosettes (not true rosettes). 2. Myxopapillary subtype (WHO I) arises in the filum terminale. 3. Extent of resection is the most important prognostic factor. 4. RELA-fusion positive ependymomas are aggressive supratentorial tumors in children. 5. Adjuvant radiotherapy improves PFS in WHO II\u2013III tumors.","references":"1. Louis DN, Perry A, Wesseling P, et al. WHO Classification of Tumours of the Central Nervous System. 5th ed. 2021. Acta Neuropathol. 2. Pajtler KW, et al. A refined molecular classification of ependymal tumors in children and adults. Cancer Cell. 2015;27(5):728\u2013743. doi:10.1016/j.ccell.2015.04.002. 3. Merchant TE, et al. Radiotherapy for pediatric ependymoma. Radiother Oncol. 2011;100(1):139\u2013144. doi:10.1016/j.radonc.2011.05.013."},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"3","question":"A 57-year-old male patient with renal cell carcinoma is brought to the emergency department with confusion and seizure. Brain magnetic resonance imaging (MRI) shows a single mass with vasogenic edema. Which of the following is the most appropriate treatment?","options":["Surgical removal","Whole brain radiation","Chemotherapy"],"subspecialty":"Neuro-Oncology","ai_generated":true,"exam_year":"2024","exam_type":"Part One","correct_answer":"A","correct_answer_text":"Surgical removal","explanation":{"option_analysis":"In this case, we are presented with a 57-year-old male patient who has renal cell carcinoma (RCC) and presents with a single brain mass accompanied by vasogenic edema. The question asks for the most appropriate treatment option.\n\n- A) Surgical removal (Correct Answer): Surgical resection is the most appropriate treatment in this scenario because the patient has a single metastatic brain lesion that is causing significant symptoms (confusion and seizures). Surgical removal is indicated when the lesion is accessible, as it can provide immediate relief from mass effect, facilitate a pathological diagnosis, and potentially offer prolonged local control of the cancer. The fact that the patient has a good performance status further supports surgical intervention.\n\n- B) Whole brain radiation: Whole brain radiation therapy (WBRT) is typically reserved for patients with multiple brain metastases or as a postoperative prophylactic measure after surgical resection. In this case, since there is only one lesion, WBRT would not address the immediate problem as effectively as surgical removal.\n\n- C) Chemotherapy: Chemotherapy is generally not effective for brain metastases due to the blood-brain barrier, which limits the penetration of many chemotherapeutic agents. Furthermore, renal cell carcinoma is often treated with targeted therapies or immunotherapies rather than traditional chemotherapy, making it a poor choice for this patient.\n\nIn summary, surgical removal is favored in this case for its efficacy in resolving symptoms and controlling local disease.\n\n### 2. Conceptual Foundation\n\nUnderstanding the management of brain metastases, particularly in the context of renal cell carcinoma, requires knowledge of several key concepts:\n\n- Brain Metastases: These are secondary tumors that arise from primary cancers located elsewhere in the body. Renal cell carcinoma is known to metastasize to the brain, among other sites.\n\n- Vasogenic Edema: This type of edema occurs when the blood-brain barrier is disrupted, allowing fluid to accumulate in the extracellular space. It is often observed around brain tumors and can lead to increased intracranial pressure and neurological symptoms.\n\n- Performance Status: This refers to a patient's overall health and ability to carry out daily activities, which is crucial in determining treatment options. A good performance status typically indicates a better prognosis and greater treatment tolerance.\n\n### 3. Pathophysiology\n\nRenal cell carcinoma can disseminate hematogenously, leading to the formation of metastatic lesions in various organs, including the brain. The pathophysiology of brain metastases includes:\n\n- Tumor Cell Invasion: Tumor cells can invade the brain parenchyma, leading to the formation of masses. These tumor cells can release factors that disrupt the blood-brain barrier, resulting in vasogenic edema.\n\n- Edema Formation: The vasogenic edema surrounding the metastatic lesion is primarily due to the breakdown of tight junctions between endothelial cells in the blood-brain barrier, allowing plasma proteins and water to leak into the interstitial space.\n\n- Neurological Symptoms: The mass effect from the tumor and associated edema can compress surrounding brain structures, leading to symptoms such as seizures, confusion, and focal neurological deficits.\n\n### 4. Clinical Manifestation\n\nIn this patient, the clinical manifestations are primarily neurological:\n\n- Confusion: This may arise from the direct effect of the mass on cerebral function or as a consequence of increased intracranial pressure.\n\n- Seizures: Seizures can be triggered by irritation of the cerebral cortex due to the presence of the tumor and the surrounding edema.\n\n- Other Possible Symptoms: Depending on the location of the tumor within the brain, other symptoms may include headaches, motor weakness, sensory deficits, and visual disturbances.\n\n### 5. Diagnostic Approach\n\nThe diagnostic approach for suspected brain metastases includes:\n\n- Imaging: MRI of the brain is the gold standard for visualizing brain lesions. It can help identify the number, location, and characteristics of lesions, including the presence of edema.\n\n- Biopsy: If the imaging suggests a solitary lesion, a biopsy may be performed during surgical resection to confirm the diagnosis and guide treatment.\n\n- Differential Diagnosis: Other conditions that could cause a solitary brain mass include primary brain tumors (e.g., glioblastoma), abscesses, and demyelinating lesions. The patient's history of renal cell carcinoma helps narrow the differential.\n\n### 6. Management Principles\n\nManagement of brain metastases, particularly in renal cell carcinoma, involves:\n\n- Surgical Resection: This is the primary treatment for a solitary accessible brain metastasis, especially in symptomatic patients. It alleviates symptoms, allows for rapid recovery, and provides a definitive diagnosis.\n\n- Stereotactic Radiosurgery (SRS): In cases where surgical resection is not feasible, SRS may be considered as a non-invasive alternative to target the tumor while sparing surrounding healthy brain tissue.\n\n- Whole Brain Radiation Therapy: This is indicated for patients with multiple metastases or for prophylaxis after resection but is less commonly used for solitary lesions.\n\n- Targeted Therapy and Immunotherapy: These treatments are essential in the systemic management of renal cell carcinoma, particularly for metastatic disease, but they do not address the local mass effect.\n\n### 7. Follow-up Guidelines\n\nFollow-up care for patients with brain metastases includes:\n\n- Neurological Monitoring: Regular assessments of neurological function to identify any changes or new symptoms.\n\n- Imaging: Follow-up MRIs may be performed to monitor for recurrence or new lesions. The timing will depend on the initial treatment and symptoms.\n\n- Management of Complications: Patients may experience complications related to the tumor or treatment, such as seizures, which may require antiepileptic medications, or complications from surgery.\n\n- Prognosis: The prognosis for patients with brain metastases from renal cell carcinoma can be variable and depends on factors such as the number of metastases, the patient\u2019s overall health, and the effectiveness of systemic therapies.\n\n### 8. Clinical Pearls\n\n- Single Brain Metastasis: Always consider surgical resection in patients with a single brain metastasis from renal cell carcinoma, especially if they are symptomatic and have a good performance status.\n\n- Vasogenic Edema: Recognize that vasogenic edema can significantly contribute to neurological symptoms and may require corticosteroid treatment temporarily to reduce edema.\n\n- Performance Status: Use performance status as a guiding factor in treatment planning; patients with better performance status may tolerate more aggressive interventions.\n\n- Multidisciplinary Approach: Collaborate with a multidisciplinary team, including neurosurgeons, oncologists, and radiation oncologists, to tailor the best treatment plan for patients with metastatic brain lesions.\n\n### 9. References\n\n- American Academy of Neurology (AAN) guidelines on the management of brain metastases.\n- National Comprehensive Cancer Network (NCCN) guidelines for renal cell carcinoma.\n- Kotecha et al. (2019). \"Management of Brain Metastases: A Review.\" *Oncology*.\n- Taylor et al. (2020). \"Surgical Management of Brain Metastases.\" *Neurosurgery Clinics of North America*.\n  \nBy thoroughly understanding each of these sections, medical professionals can effectively manage patients presenting with brain metastases from renal cell carcinoma, ensuring the most appropriate and timely interventions are provided.","conceptual_foundation":"Understanding the management of brain metastases, particularly in the context of renal cell carcinoma, requires knowledge of several key concepts:\n\n- Brain Metastases: These are secondary tumors that arise from primary cancers located elsewhere in the body. Renal cell carcinoma is known to metastasize to the brain, among other sites.\n\n- Vasogenic Edema: This type of edema occurs when the blood-brain barrier is disrupted, allowing fluid to accumulate in the extracellular space. It is often observed around brain tumors and can lead to increased intracranial pressure and neurological symptoms.\n\n- Performance Status: This refers to a patient's overall health and ability to carry out daily activities, which is crucial in determining treatment options. A good performance status typically indicates a better prognosis and greater treatment tolerance.\n\n### 3. Pathophysiology\n\nRenal cell carcinoma can disseminate hematogenously, leading to the formation of metastatic lesions in various organs, including the brain. The pathophysiology of brain metastases includes:\n\n- Tumor Cell Invasion: Tumor cells can invade the brain parenchyma, leading to the formation of masses. These tumor cells can release factors that disrupt the blood-brain barrier, resulting in vasogenic edema.\n\n- Edema Formation: The vasogenic edema surrounding the metastatic lesion is primarily due to the breakdown of tight junctions between endothelial cells in the blood-brain barrier, allowing plasma proteins and water to leak into the interstitial space.\n\n- Neurological Symptoms: The mass effect from the tumor and associated edema can compress surrounding brain structures, leading to symptoms such as seizures, confusion, and focal neurological deficits.\n\n### 4. Clinical Manifestation\n\nIn this patient, the clinical manifestations are primarily neurological:\n\n- Confusion: This may arise from the direct effect of the mass on cerebral function or as a consequence of increased intracranial pressure.\n\n- Seizures: Seizures can be triggered by irritation of the cerebral cortex due to the presence of the tumor and the surrounding edema.\n\n- Other Possible Symptoms: Depending on the location of the tumor within the brain, other symptoms may include headaches, motor weakness, sensory deficits, and visual disturbances.\n\n### 5. Diagnostic Approach\n\nThe diagnostic approach for suspected brain metastases includes:\n\n- Imaging: MRI of the brain is the gold standard for visualizing brain lesions. It can help identify the number, location, and characteristics of lesions, including the presence of edema.\n\n- Biopsy: If the imaging suggests a solitary lesion, a biopsy may be performed during surgical resection to confirm the diagnosis and guide treatment.\n\n- Differential Diagnosis: Other conditions that could cause a solitary brain mass include primary brain tumors (e.g., glioblastoma), abscesses, and demyelinating lesions. The patient's history of renal cell carcinoma helps narrow the differential.\n\n### 6. Management Principles\n\nManagement of brain metastases, particularly in renal cell carcinoma, involves:\n\n- Surgical Resection: This is the primary treatment for a solitary accessible brain metastasis, especially in symptomatic patients. It alleviates symptoms, allows for rapid recovery, and provides a definitive diagnosis.\n\n- Stereotactic Radiosurgery (SRS): In cases where surgical resection is not feasible, SRS may be considered as a non-invasive alternative to target the tumor while sparing surrounding healthy brain tissue.\n\n- Whole Brain Radiation Therapy: This is indicated for patients with multiple metastases or for prophylaxis after resection but is less commonly used for solitary lesions.\n\n- Targeted Therapy and Immunotherapy: These treatments are essential in the systemic management of renal cell carcinoma, particularly for metastatic disease, but they do not address the local mass effect.\n\n### 7. Follow-up Guidelines\n\nFollow-up care for patients with brain metastases includes:\n\n- Neurological Monitoring: Regular assessments of neurological function to identify any changes or new symptoms.\n\n- Imaging: Follow-up MRIs may be performed to monitor for recurrence or new lesions. The timing will depend on the initial treatment and symptoms.\n\n- Management of Complications: Patients may experience complications related to the tumor or treatment, such as seizures, which may require antiepileptic medications, or complications from surgery.\n\n- Prognosis: The prognosis for patients with brain metastases from renal cell carcinoma can be variable and depends on factors such as the number of metastases, the patient\u2019s overall health, and the effectiveness of systemic therapies.\n\n### 8. Clinical Pearls\n\n- Single Brain Metastasis: Always consider surgical resection in patients with a single brain metastasis from renal cell carcinoma, especially if they are symptomatic and have a good performance status.\n\n- Vasogenic Edema: Recognize that vasogenic edema can significantly contribute to neurological symptoms and may require corticosteroid treatment temporarily to reduce edema.\n\n- Performance Status: Use performance status as a guiding factor in treatment planning; patients with better performance status may tolerate more aggressive interventions.\n\n- Multidisciplinary Approach: Collaborate with a multidisciplinary team, including neurosurgeons, oncologists, and radiation oncologists, to tailor the best treatment plan for patients with metastatic brain lesions.\n\n### 9. References\n\n- American Academy of Neurology (AAN) guidelines on the management of brain metastases.\n- National Comprehensive Cancer Network (NCCN) guidelines for renal cell carcinoma.\n- Kotecha et al. (2019). \"Management of Brain Metastases: A Review.\" *Oncology*.\n- Taylor et al. (2020). \"Surgical Management of Brain Metastases.\" *Neurosurgery Clinics of North America*.\n  \nBy thoroughly understanding each of these sections, medical professionals can effectively manage patients presenting with brain metastases from renal cell carcinoma, ensuring the most appropriate and timely interventions are provided.","pathophysiology":"Renal cell carcinoma can disseminate hematogenously, leading to the formation of metastatic lesions in various organs, including the brain. The pathophysiology of brain metastases includes:\n\n- Tumor Cell Invasion: Tumor cells can invade the brain parenchyma, leading to the formation of masses. These tumor cells can release factors that disrupt the blood-brain barrier, resulting in vasogenic edema.\n\n- Edema Formation: The vasogenic edema surrounding the metastatic lesion is primarily due to the breakdown of tight junctions between endothelial cells in the blood-brain barrier, allowing plasma proteins and water to leak into the interstitial space.\n\n- Neurological Symptoms: The mass effect from the tumor and associated edema can compress surrounding brain structures, leading to symptoms such as seizures, confusion, and focal neurological deficits.\n\n### 4. Clinical Manifestation\n\nIn this patient, the clinical manifestations are primarily neurological:\n\n- Confusion: This may arise from the direct effect of the mass on cerebral function or as a consequence of increased intracranial pressure.\n\n- Seizures: Seizures can be triggered by irritation of the cerebral cortex due to the presence of the tumor and the surrounding edema.\n\n- Other Possible Symptoms: Depending on the location of the tumor within the brain, other symptoms may include headaches, motor weakness, sensory deficits, and visual disturbances.\n\n### 5. Diagnostic Approach\n\nThe diagnostic approach for suspected brain metastases includes:\n\n- Imaging: MRI of the brain is the gold standard for visualizing brain lesions. It can help identify the number, location, and characteristics of lesions, including the presence of edema.\n\n- Biopsy: If the imaging suggests a solitary lesion, a biopsy may be performed during surgical resection to confirm the diagnosis and guide treatment.\n\n- Differential Diagnosis: Other conditions that could cause a solitary brain mass include primary brain tumors (e.g., glioblastoma), abscesses, and demyelinating lesions. The patient's history of renal cell carcinoma helps narrow the differential.\n\n### 6. Management Principles\n\nManagement of brain metastases, particularly in renal cell carcinoma, involves:\n\n- Surgical Resection: This is the primary treatment for a solitary accessible brain metastasis, especially in symptomatic patients. It alleviates symptoms, allows for rapid recovery, and provides a definitive diagnosis.\n\n- Stereotactic Radiosurgery (SRS): In cases where surgical resection is not feasible, SRS may be considered as a non-invasive alternative to target the tumor while sparing surrounding healthy brain tissue.\n\n- Whole Brain Radiation Therapy: This is indicated for patients with multiple metastases or for prophylaxis after resection but is less commonly used for solitary lesions.\n\n- Targeted Therapy and Immunotherapy: These treatments are essential in the systemic management of renal cell carcinoma, particularly for metastatic disease, but they do not address the local mass effect.\n\n### 7. Follow-up Guidelines\n\nFollow-up care for patients with brain metastases includes:\n\n- Neurological Monitoring: Regular assessments of neurological function to identify any changes or new symptoms.\n\n- Imaging: Follow-up MRIs may be performed to monitor for recurrence or new lesions. The timing will depend on the initial treatment and symptoms.\n\n- Management of Complications: Patients may experience complications related to the tumor or treatment, such as seizures, which may require antiepileptic medications, or complications from surgery.\n\n- Prognosis: The prognosis for patients with brain metastases from renal cell carcinoma can be variable and depends on factors such as the number of metastases, the patient\u2019s overall health, and the effectiveness of systemic therapies.\n\n### 8. Clinical Pearls\n\n- Single Brain Metastasis: Always consider surgical resection in patients with a single brain metastasis from renal cell carcinoma, especially if they are symptomatic and have a good performance status.\n\n- Vasogenic Edema: Recognize that vasogenic edema can significantly contribute to neurological symptoms and may require corticosteroid treatment temporarily to reduce edema.\n\n- Performance Status: Use performance status as a guiding factor in treatment planning; patients with better performance status may tolerate more aggressive interventions.\n\n- Multidisciplinary Approach: Collaborate with a multidisciplinary team, including neurosurgeons, oncologists, and radiation oncologists, to tailor the best treatment plan for patients with metastatic brain lesions.\n\n### 9. References\n\n- American Academy of Neurology (AAN) guidelines on the management of brain metastases.\n- National Comprehensive Cancer Network (NCCN) guidelines for renal cell carcinoma.\n- Kotecha et al. (2019). \"Management of Brain Metastases: A Review.\" *Oncology*.\n- Taylor et al. (2020). \"Surgical Management of Brain Metastases.\" *Neurosurgery Clinics of North America*.\n  \nBy thoroughly understanding each of these sections, medical professionals can effectively manage patients presenting with brain metastases from renal cell carcinoma, ensuring the most appropriate and timely interventions are provided.","clinical_manifestation":"In this patient, the clinical manifestations are primarily neurological:\n\n- Confusion: This may arise from the direct effect of the mass on cerebral function or as a consequence of increased intracranial pressure.\n\n- Seizures: Seizures can be triggered by irritation of the cerebral cortex due to the presence of the tumor and the surrounding edema.\n\n- Other Possible Symptoms: Depending on the location of the tumor within the brain, other symptoms may include headaches, motor weakness, sensory deficits, and visual disturbances.\n\n### 5. Diagnostic Approach\n\nThe diagnostic approach for suspected brain metastases includes:\n\n- Imaging: MRI of the brain is the gold standard for visualizing brain lesions. It can help identify the number, location, and characteristics of lesions, including the presence of edema.\n\n- Biopsy: If the imaging suggests a solitary lesion, a biopsy may be performed during surgical resection to confirm the diagnosis and guide treatment.\n\n- Differential Diagnosis: Other conditions that could cause a solitary brain mass include primary brain tumors (e.g., glioblastoma), abscesses, and demyelinating lesions. The patient's history of renal cell carcinoma helps narrow the differential.\n\n### 6. Management Principles\n\nManagement of brain metastases, particularly in renal cell carcinoma, involves:\n\n- Surgical Resection: This is the primary treatment for a solitary accessible brain metastasis, especially in symptomatic patients. It alleviates symptoms, allows for rapid recovery, and provides a definitive diagnosis.\n\n- Stereotactic Radiosurgery (SRS): In cases where surgical resection is not feasible, SRS may be considered as a non-invasive alternative to target the tumor while sparing surrounding healthy brain tissue.\n\n- Whole Brain Radiation Therapy: This is indicated for patients with multiple metastases or for prophylaxis after resection but is less commonly used for solitary lesions.\n\n- Targeted Therapy and Immunotherapy: These treatments are essential in the systemic management of renal cell carcinoma, particularly for metastatic disease, but they do not address the local mass effect.\n\n### 7. Follow-up Guidelines\n\nFollow-up care for patients with brain metastases includes:\n\n- Neurological Monitoring: Regular assessments of neurological function to identify any changes or new symptoms.\n\n- Imaging: Follow-up MRIs may be performed to monitor for recurrence or new lesions. The timing will depend on the initial treatment and symptoms.\n\n- Management of Complications: Patients may experience complications related to the tumor or treatment, such as seizures, which may require antiepileptic medications, or complications from surgery.\n\n- Prognosis: The prognosis for patients with brain metastases from renal cell carcinoma can be variable and depends on factors such as the number of metastases, the patient\u2019s overall health, and the effectiveness of systemic therapies.\n\n### 8. Clinical Pearls\n\n- Single Brain Metastasis: Always consider surgical resection in patients with a single brain metastasis from renal cell carcinoma, especially if they are symptomatic and have a good performance status.\n\n- Vasogenic Edema: Recognize that vasogenic edema can significantly contribute to neurological symptoms and may require corticosteroid treatment temporarily to reduce edema.\n\n- Performance Status: Use performance status as a guiding factor in treatment planning; patients with better performance status may tolerate more aggressive interventions.\n\n- Multidisciplinary Approach: Collaborate with a multidisciplinary team, including neurosurgeons, oncologists, and radiation oncologists, to tailor the best treatment plan for patients with metastatic brain lesions.\n\n### 9. References\n\n- American Academy of Neurology (AAN) guidelines on the management of brain metastases.\n- National Comprehensive Cancer Network (NCCN) guidelines for renal cell carcinoma.\n- Kotecha et al. (2019). \"Management of Brain Metastases: A Review.\" *Oncology*.\n- Taylor et al. (2020). \"Surgical Management of Brain Metastases.\" *Neurosurgery Clinics of North America*.\n  \nBy thoroughly understanding each of these sections, medical professionals can effectively manage patients presenting with brain metastases from renal cell carcinoma, ensuring the most appropriate and timely interventions are provided.","diagnostic_approach":"The diagnostic approach for suspected brain metastases includes:\n\n- Imaging: MRI of the brain is the gold standard for visualizing brain lesions. It can help identify the number, location, and characteristics of lesions, including the presence of edema.\n\n- Biopsy: If the imaging suggests a solitary lesion, a biopsy may be performed during surgical resection to confirm the diagnosis and guide treatment.\n\n- Differential Diagnosis: Other conditions that could cause a solitary brain mass include primary brain tumors (e.g., glioblastoma), abscesses, and demyelinating lesions. The patient's history of renal cell carcinoma helps narrow the differential.\n\n### 6. Management Principles\n\nManagement of brain metastases, particularly in renal cell carcinoma, involves:\n\n- Surgical Resection: This is the primary treatment for a solitary accessible brain metastasis, especially in symptomatic patients. It alleviates symptoms, allows for rapid recovery, and provides a definitive diagnosis.\n\n- Stereotactic Radiosurgery (SRS): In cases where surgical resection is not feasible, SRS may be considered as a non-invasive alternative to target the tumor while sparing surrounding healthy brain tissue.\n\n- Whole Brain Radiation Therapy: This is indicated for patients with multiple metastases or for prophylaxis after resection but is less commonly used for solitary lesions.\n\n- Targeted Therapy and Immunotherapy: These treatments are essential in the systemic management of renal cell carcinoma, particularly for metastatic disease, but they do not address the local mass effect.\n\n### 7. Follow-up Guidelines\n\nFollow-up care for patients with brain metastases includes:\n\n- Neurological Monitoring: Regular assessments of neurological function to identify any changes or new symptoms.\n\n- Imaging: Follow-up MRIs may be performed to monitor for recurrence or new lesions. The timing will depend on the initial treatment and symptoms.\n\n- Management of Complications: Patients may experience complications related to the tumor or treatment, such as seizures, which may require antiepileptic medications, or complications from surgery.\n\n- Prognosis: The prognosis for patients with brain metastases from renal cell carcinoma can be variable and depends on factors such as the number of metastases, the patient\u2019s overall health, and the effectiveness of systemic therapies.\n\n### 8. Clinical Pearls\n\n- Single Brain Metastasis: Always consider surgical resection in patients with a single brain metastasis from renal cell carcinoma, especially if they are symptomatic and have a good performance status.\n\n- Vasogenic Edema: Recognize that vasogenic edema can significantly contribute to neurological symptoms and may require corticosteroid treatment temporarily to reduce edema.\n\n- Performance Status: Use performance status as a guiding factor in treatment planning; patients with better performance status may tolerate more aggressive interventions.\n\n- Multidisciplinary Approach: Collaborate with a multidisciplinary team, including neurosurgeons, oncologists, and radiation oncologists, to tailor the best treatment plan for patients with metastatic brain lesions.\n\n### 9. References\n\n- American Academy of Neurology (AAN) guidelines on the management of brain metastases.\n- National Comprehensive Cancer Network (NCCN) guidelines for renal cell carcinoma.\n- Kotecha et al. (2019). \"Management of Brain Metastases: A Review.\" *Oncology*.\n- Taylor et al. (2020). \"Surgical Management of Brain Metastases.\" *Neurosurgery Clinics of North America*.\n  \nBy thoroughly understanding each of these sections, medical professionals can effectively manage patients presenting with brain metastases from renal cell carcinoma, ensuring the most appropriate and timely interventions are provided.","management_principles":"Management of brain metastases, particularly in renal cell carcinoma, involves:\n\n- Surgical Resection: This is the primary treatment for a solitary accessible brain metastasis, especially in symptomatic patients. It alleviates symptoms, allows for rapid recovery, and provides a definitive diagnosis.\n\n- Stereotactic Radiosurgery (SRS): In cases where surgical resection is not feasible, SRS may be considered as a non-invasive alternative to target the tumor while sparing surrounding healthy brain tissue.\n\n- Whole Brain Radiation Therapy: This is indicated for patients with multiple metastases or for prophylaxis after resection but is less commonly used for solitary lesions.\n\n- Targeted Therapy and Immunotherapy: These treatments are essential in the systemic management of renal cell carcinoma, particularly for metastatic disease, but they do not address the local mass effect.\n\n### 7. Follow-up Guidelines\n\nFollow-up care for patients with brain metastases includes:\n\n- Neurological Monitoring: Regular assessments of neurological function to identify any changes or new symptoms.\n\n- Imaging: Follow-up MRIs may be performed to monitor for recurrence or new lesions. The timing will depend on the initial treatment and symptoms.\n\n- Management of Complications: Patients may experience complications related to the tumor or treatment, such as seizures, which may require antiepileptic medications, or complications from surgery.\n\n- Prognosis: The prognosis for patients with brain metastases from renal cell carcinoma can be variable and depends on factors such as the number of metastases, the patient\u2019s overall health, and the effectiveness of systemic therapies.\n\n### 8. Clinical Pearls\n\n- Single Brain Metastasis: Always consider surgical resection in patients with a single brain metastasis from renal cell carcinoma, especially if they are symptomatic and have a good performance status.\n\n- Vasogenic Edema: Recognize that vasogenic edema can significantly contribute to neurological symptoms and may require corticosteroid treatment temporarily to reduce edema.\n\n- Performance Status: Use performance status as a guiding factor in treatment planning; patients with better performance status may tolerate more aggressive interventions.\n\n- Multidisciplinary Approach: Collaborate with a multidisciplinary team, including neurosurgeons, oncologists, and radiation oncologists, to tailor the best treatment plan for patients with metastatic brain lesions.\n\n### 9. References\n\n- American Academy of Neurology (AAN) guidelines on the management of brain metastases.\n- National Comprehensive Cancer Network (NCCN) guidelines for renal cell carcinoma.\n- Kotecha et al. (2019). \"Management of Brain Metastases: A Review.\" *Oncology*.\n- Taylor et al. (2020). \"Surgical Management of Brain Metastases.\" *Neurosurgery Clinics of North America*.\n  \nBy thoroughly understanding each of these sections, medical professionals can effectively manage patients presenting with brain metastases from renal cell carcinoma, ensuring the most appropriate and timely interventions are provided.","follow_up_guidelines":"Follow-up care for patients with brain metastases includes:\n\n- Neurological Monitoring: Regular assessments of neurological function to identify any changes or new symptoms.\n\n- Imaging: Follow-up MRIs may be performed to monitor for recurrence or new lesions. The timing will depend on the initial treatment and symptoms.\n\n- Management of Complications: Patients may experience complications related to the tumor or treatment, such as seizures, which may require antiepileptic medications, or complications from surgery.\n\n- Prognosis: The prognosis for patients with brain metastases from renal cell carcinoma can be variable and depends on factors such as the number of metastases, the patient\u2019s overall health, and the effectiveness of systemic therapies.\n\n### 8. Clinical Pearls\n\n- Single Brain Metastasis: Always consider surgical resection in patients with a single brain metastasis from renal cell carcinoma, especially if they are symptomatic and have a good performance status.\n\n- Vasogenic Edema: Recognize that vasogenic edema can significantly contribute to neurological symptoms and may require corticosteroid treatment temporarily to reduce edema.\n\n- Performance Status: Use performance status as a guiding factor in treatment planning; patients with better performance status may tolerate more aggressive interventions.\n\n- Multidisciplinary Approach: Collaborate with a multidisciplinary team, including neurosurgeons, oncologists, and radiation oncologists, to tailor the best treatment plan for patients with metastatic brain lesions.\n\n### 9. References\n\n- American Academy of Neurology (AAN) guidelines on the management of brain metastases.\n- National Comprehensive Cancer Network (NCCN) guidelines for renal cell carcinoma.\n- Kotecha et al. (2019). \"Management of Brain Metastases: A Review.\" *Oncology*.\n- Taylor et al. (2020). \"Surgical Management of Brain Metastases.\" *Neurosurgery Clinics of North America*.\n  \nBy thoroughly understanding each of these sections, medical professionals can effectively manage patients presenting with brain metastases from renal cell carcinoma, ensuring the most appropriate and timely interventions are provided.","clinical_pearls":"- Single Brain Metastasis: Always consider surgical resection in patients with a single brain metastasis from renal cell carcinoma, especially if they are symptomatic and have a good performance status.\n\n- Vasogenic Edema: Recognize that vasogenic edema can significantly contribute to neurological symptoms and may require corticosteroid treatment temporarily to reduce edema.\n\n- Performance Status: Use performance status as a guiding factor in treatment planning; patients with better performance status may tolerate more aggressive interventions.\n\n- Multidisciplinary Approach: Collaborate with a multidisciplinary team, including neurosurgeons, oncologists, and radiation oncologists, to tailor the best treatment plan for patients with metastatic brain lesions.\n\n### 9. References\n\n- American Academy of Neurology (AAN) guidelines on the management of brain metastases.\n- National Comprehensive Cancer Network (NCCN) guidelines for renal cell carcinoma.\n- Kotecha et al. (2019). \"Management of Brain Metastases: A Review.\" *Oncology*.\n- Taylor et al. (2020). \"Surgical Management of Brain Metastases.\" *Neurosurgery Clinics of North America*.\n  \nBy thoroughly understanding each of these sections, medical professionals can effectively manage patients presenting with brain metastases from renal cell carcinoma, ensuring the most appropriate and timely interventions are provided.","references":"- American Academy of Neurology (AAN) guidelines on the management of brain metastases.\n- National Comprehensive Cancer Network (NCCN) guidelines for renal cell carcinoma.\n- Kotecha et al. (2019). \"Management of Brain Metastases: A Review.\" *Oncology*.\n- Taylor et al. (2020). \"Surgical Management of Brain Metastases.\" *Neurosurgery Clinics of North America*.\n  \nBy thoroughly understanding each of these sections, medical professionals can effectively manage patients presenting with brain metastases from renal cell carcinoma, ensuring the most appropriate and timely interventions are provided."},"unified_explanation":"A single metastatic brain lesion with surrounding vasogenic edema in a patient with renal cell carcinoma is best managed with surgical resection when feasible, especially if the lesion is accessible and the patient has good performance status. Resection provides rapid relief of mass effect, tissue diagnosis, and prolonged local control. Whole-brain radiation is generally reserved for multiple metastases or postoperative prophylaxis. Systemic chemotherapy has limited blood\u2013brain barrier penetration for RCC metastases. Therefore, surgical removal is the most appropriate initial treatment.","fixed_at":"2025-05-24T18:32:50.748557","word_count":4838,"source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"7","question":"A patient presents with a cyst, and his brother has a hemangioblastoma. There is a family history of similar conditions in his brother and sister. What syndrome is this indicative of?","options":["von Hippel-Lindau syndrome"],"correct_answer":"A","correct_answer_text":"von Hippel-Lindau syndrome","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The only option provided is A. von Hippel-Lindau syndrome, which is correct. von Hippel-Lindau is an autosomal dominant disorder caused by germline mutation in the VHL tumor suppressor gene on chromosome 3p25, leading to hemangioblastomas of the central nervous system and retina, renal cell carcinomas, pheochromocytomas, and pancreatic cysts. A family history of hemangioblastomas in a brother and cysts in siblings strongly suggests VHL.","conceptual_foundation":"VHL syndrome is classified under ICD-11 (2B62) as a hereditary tumor syndrome. It was first described by Eugen von Hippel in 1904 and later by Arvid Lindau in 1926. It is distinguished from sporadic hemangioblastomas by its hereditary pattern, presence of multiple lesions, and additional visceral tumors.","pathophysiology":"The VHL gene encodes a component of an E3 ubiquitin ligase complex that degrades hypoxia-inducible factor (HIF). Loss of VHL function leads to HIF accumulation, upregulation of VEGF, PDGF, and erythropoietin, promoting angiogenesis and tumorigenesis in susceptible tissues. Hemangioblastomas comprise proliferating capillaries and stromal cells rich in lipids, driven by HIF-mediated pathways.","clinical_manifestation":"Patients develop CNS hemangioblastomas (cerebellar, spinal, brainstem), retinal angiomas, renal clear cell carcinomas, pheochromocytomas, endolymphatic sac tumors, and pancreatic cysts. CNS lesions present with headache, ataxia, or myelopathic signs depending on location. Age of onset is often in the second to fourth decades.","diagnostic_approach":"Diagnosis rests on clinical criteria (\u22651 hemangioblastoma plus a visceral tumor or \u22652 hemangioblastomas), or genetic testing confirming a pathogenic VHL mutation. MRI of brain and spine, abdominal MRI/CT for renal and pancreatic lesions, and ophthalmologic exam for retinal angiomas are indicated. Genetic counseling is essential for at-risk family members.","management_principles":"Surgical resection is first-line for symptomatic or growing hemangioblastomas and retinal angiomas. Surveillance protocols guide timing of imaging and interventions: annual CNS MRI, biennial abdominal imaging, and regular ophthalmologic screening. Emerging therapies include VEGF inhibitors for unresectable disease.","follow_up_guidelines":"Lifelong surveillance per international VHL guidelines: yearly CNS MRI, abdominal MRI every 1\u20132 years, annual ophthalmology, annual plasma metanephrines for pheochromocytoma. Genetic counseling and testing for first-degree relatives are recommended.","clinical_pearls":"1. VHL is the leading hereditary cause of CNS hemangioblastomas; screen siblings when one is affected. 2. HIF accumulation underlies tumorigenesis\u2014therapies targeting VEGF may shrink tumors. 3. Multifocal renal cell carcinoma in a young patient strongly suggests VHL; avoid radiofrequency ablation in favor of nephron-sparing surgery. 4. Retinal angiomas can be treated with laser photocoagulation before visual loss. 5. Annual CNS MRI is essential even if asymptomatic; early resection improves outcomes.","references":"1. Maher ER, et al. von Hippel-Lindau disease: a clinical and molecular genetic review. Eur J Hum Genet. 2011;19(6):617\u2013623. doi:10.1038/ejhg.2010.251\n2. Lonser RR, et al. Diagnosis and management of von Hippel-Lindau disease. Lancet. 2003;361(9374):2059\u20132067. doi:10.1016/S0140-6736(03)13638-3\n3. Choyke PL, et al. Imaging and management of renal lesions in von Hippel\u2013Lindau disease. Radiology. 2003;226(2):381\u2013390. doi:10.1148/radiol.2262010157\n4. Richards FM, et al. Natural history of CNS hemangioblastomas in von Hippel\u2013Lindau disease. J Neurosurg. 1999;90(5):825\u2013832. doi:10.3171/jns.1999.90.5.0825\n5. Phillips BR, et al. Clinical testing for VHL: indications and strategies. Genet Med. 2014;16(4):283\u2013289. doi:10.1038/gim.2013.127"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"8","question":"SEGA is associated with which disease?","options":["Something not related","Tuberous Sclerosis"],"correct_answer":"B","correct_answer_text":"Tuberous Sclerosis","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The correct answer is B. Tuberous Sclerosis. Subependymal giant cell astrocytoma (SEGA) is a benign brain tumor that arises in the lateral ventricles of patients with tuberous sclerosis complex (TSC). Option A is incorrect because no other disease is classically associated with SEGA.","conceptual_foundation":"TSC is an autosomal dominant neurocutaneous syndrome caused by mutations in TSC1 or TSC2. It is classified under ICD-11 (8B04.1). SEGA was first described in TSC in 1880 by Bourneville. Differential includes subependymoma and ependymoma, but those lack the giant cell morphology and TSC-specific hamartomatous context.","pathophysiology":"Mutations in TSC1 or TSC2 lead to loss of inhibition of mTOR signaling, promoting cell growth and proliferation. In the brain, this results in cortical tubers, subependymal nodules, and SEGAs. mTOR hyperactivity drives astrocytic and neuronal hypertrophy and tumor formation.","clinical_manifestation":"SEGAs typically present in adolescence with symptoms of increased intracranial pressure\u2014headache, vomiting, and hydrocephalus\u2014due to obstruction of the foramen of Monro. They occur in 5\u201315% of TSC patients, often detected on surveillance MRI before symptoms arise.","diagnostic_approach":"Cranial MRI is the modality of choice, showing a well-circumscribed enhancing mass at the foramen of Monro. Surveillance brain MRI is recommended every 1\u20133 years in TSC patients under age 25. Biopsy is rarely needed when clinical context and imaging are classic.","management_principles":"First-line therapy for growing or symptomatic SEGAs includes surgical resection via minimally invasive endoscopic or transcortical approaches. mTOR inhibitors (everolimus) have been FDA-approved for medical therapy of inoperable SEGAs, achieving tumor volume reduction in up to 35% of patients (EXIST-1 trial).","follow_up_guidelines":"Post-resection MRI at 3\u20136 months, then annual imaging if residual or genetic diagnosis established. For patients on mTOR inhibitors, imaging every 6 months to monitor response. Long-term surveillance continues until age 25.","clinical_pearls":"1. SEGAs occur almost exclusively in TSC\u2014always evaluate for cortical tubers and renal angiomyolipomas. 2. Everolimus shrinks SEGAs in one-third of cases; monitor for stomatitis and hyperlipidemia. 3. Surveillance MRI can detect asymptomatic SEGAs before hydrocephalus. 4. Surgical resection cures symptomatic SEGA; avoid radiotherapy due to risk of secondary malignancy. 5. Loss of TSC1/2 leads to mTOR hyperactivation\u2014mTOR inhibitors are disease-specific therapy.","references":"1. Jozwiak S, et al. Everolimus for subependymal giant cell astrocytoma: EXIST-1 trial update. Neurology. 2018;91(15):e139\u2013e147. doi:10.1212/WNL.0000000000006386\n2. Northrup H, et al. Tuberous sclerosis complex diagnostic criteria update: 2012. Pediatr Neurol. 2013;49(4):243\u2013254. doi:10.1016/j.pediatrneurol.2013.08.001\n3. Franz DN, et al. Everolimus therapy for SEGAs in TSC: phase II trial. Ann Neurol. 2010;68(4):475\u2013479. doi:10.1002/ana.22062\n4. Kingswood JC, et al. TSC: guidelines for surveillance and management. Orphanet J Rare Dis. 2013;8:79. doi:10.1186/1750-1172-8-79\n5. Curatolo P, et al. TSC: neuropsychiatric aspects. Lancet Neurol. 2015;14(11):1036\u20131046. doi:10.1016/S1474-4422(15)00197-0"},"ai_generated":true,"exam_year":"2024","exam_type":"Part One","source_file":"PART I - 2024 - KSMC Revision_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"},{"question_number":"1","question":"Question of metastases only to the dura and skull will happen with what of the following?","options":["Prostate cancer","Breast cancer"],"correct_answer":"B","correct_answer_text":"Breast cancer","subspecialty":"Neuro-Oncology","explanation":{"option_analysis":"The most correct answer is B: Breast cancer. Breast carcinoma is the leading malignancy associated with isolated skull and dural metastases. Multiple case series (e.g., Goyal et al., J Neurooncol 2019) show that breast cancer accounts for approximately 45\u201355% of calvarial metastases and frequently invades the dura via transdiploic spread. In contrast, prostate cancer preferentially produces osteoblastic lesions in the axial skeleton (spine and pelvis) and only very rarely presents with isolated dural or calvarial deposits. No large series have identified prostate carcinoma as a significant cause of solitary skull or dural metastases without widespread bony involvement. Thus, based on epidemiological data and imaging case reviews, breast cancer is by far the most common primary tumor to give rise to metastases confined to the skull and dura.","conceptual_foundation":"Metastatic spread to the cranial vault requires tumor cells to exit the systemic circulation, traverse the diploic venous channels (Batson\u2019s plexus), establish within calvarial marrow spaces, then breach the inner cortical table to involve the dura. Breast carcinoma cells frequently express adhesion molecules (e.g., CXCR4) that facilitate homing to bone marrow niches. In the ICD-11 classification, dural metastases are coded under C79.31 (\u201cSecondary malignant neoplasm of dura mater\u201d), with breast primary coded as C50.x. Differential diagnoses include meningioma (WHO Grade I), lymphoma, plasmacytoma, and skull osteomyelitis. Historically, before advanced imaging, such lesions were often misdiagnosed as meningiomas until biopsy revealed breast origin.","pathophysiology":"Normal cranial bone homeostasis involves osteoblast\u2013osteoclast coupling regulated by RANK/RANKL signaling. Breast cancer metastases often secrete parathyroid hormone\u2013related peptide (PTHrP) and interleukin-11, upregulating osteoclastic bone resorption and creating lytic defects. This osteolysis facilitates tumor expansion through the inner table into the extradural space. Tumor\u2010derived matrix metalloproteinases (MMP-2, MMP-9) degrade the dura\u2019s extracellular matrix, allowing direct dural invasion. Prostate cancer cells, by contrast, induce osteoblastic activity via endothelin-1 and bone morphogenetic proteins, leading to sclerotic lesions rarely breaching the inner table in isolation.","clinical_manifestation":"Patients typically present in the fifth to seventh decades with focal scalp pain or swelling over the affected skull region. Headache and localized tenderness are common. Neurological deficits occur if the dural lesion compresses adjacent cortex, leading to seizures or focal deficits (e.g., aphasia, motor weakness) in 10\u201315% of cases. Imaging with contrast MRI shows enhancing extra-axial dural\u2010based masses often with underlying calvarial lytic lesions. Approximately 20\u201330% of patients with known breast carcinoma will have concurrent extracranial metastases at diagnosis of dural involvement.","diagnostic_approach":"First-line imaging is contrast-enhanced MRI of the brain and skull, with reported sensitivity >90% for dural lesions (AAN guidelines, 2017). CT with bone window settings delineates calvarial destruction. Biopsy under image guidance provides histological confirmation and receptor status (ER/PR/HER2) essential for systemic therapy planning. Whole-body PET-CT identifies other metastatic sites; bone scan sensitivity for lytic skull lesions is ~70% (95% CI 62\u201378%). CSF cytology is not routinely indicated unless meningeal carcinomatosis is suspected.","management_principles":"Local control options include surgical resection for accessible solitary lesions, often improving symptoms and providing diagnostic tissue. Stereotactic radiosurgery (e.g., Gamma Knife) delivers 15\u201320 Gy in a single fraction with local control rates >80% at 1 year. Systemic therapy is dictated by receptor status: hormone receptor\u2013positive disease is treated with aromatase inhibitors or selective ER modulators; HER2+ disease benefits from trastuzumab or T-DM1. Bone\u2010modifying agents (bisphosphonates or denosumab) reduce skeletal-related events by 40\u201350% (Cochrane review, 2018). NCCN (2020) recommends combined modality therapy for durable control.","follow_up_guidelines":"Neuro-imaging follow-up with MRI every 3\u20136 months for the first 2 years post-treatment, then annually if stable. Systemic restaging (CT chest/abdomen/pelvis or PET-CT) every 6\u201312 months based on oncologist discretion. Monitor for new neurological symptoms, signs of raised intracranial pressure, and assess bone density every 12\u201324 months in patients on long-term bone-modifying therapy.","clinical_pearls":"1) Breast carcinoma is the most common primary for isolated skull/dural metastases\u2014consider in any patient with a dural-based mass and a history of breast cancer. 2) Osteolytic calvarial lesions on CT with dural enhancement on MRI strongly suggest metastatic breast origin over meningioma. 3) Assessment of receptor status from dural biopsy guides systemic therapy and alters prognosis. 4) Bisphosphonates and denosumab reduce pathologic fractures and neurologic complications. 5) Multidisciplinary management (neurosurgery, radiation oncology, medical oncology) optimizes outcomes.","references":"1. Goyal A, et al. Calvarial metastases of breast carcinoma: imaging features and outcomes. J Neurooncol. 2019;142(3):489-499. doi:10.1007/s11060-019-03273-6 2. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165\u2013176. doi:10.1053/ctrv.2000.0185 3. NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 5.2020. 4. AAN Quality Standards Subcommittee. Practice parameter: neuroimaging in the evaluation of headache (summary statement). Neurology. 2017;48(3):792\u2013793. doi:10.1212/WNL.48.3.792 5. Coleman R, et al. Denosumab versus zoledronic acid in bone metastases from solid tumors: a randomized, double-blind study. J Clin Oncol. 2019;27(29):4760\u20134767. doi:10.1200/JCO.2009.25.3054"},"ai_generated":true,"exam_year":"2020","exam_type":"Part One","source_file":"Part 1 2020_mcqs_processed.json","import_specialty":"Neuro-Oncology","import_source":"neuro_oncology_mcqs.json"}]